FDA 510(k)/De Novo and QML Neuroimaging for Alzheimer's - Discussion 57

Explore the intricacies of FDA approval processes for Quantum Machine Learning (QML) Software as Medical Devices (SaMD) in neuroimaging for Alzheimer's disease. Delve into the distinctions between 510(k) and De Novo classifications, examining recent FDA approvals in radiology AI/ML applications. Analyze case studies of approved devices, including CT image reconstruction software and portable MR imaging systems utilizing deep learning. Investigate a De Novo classified pediatric Autism Spectrum Disorder diagnosis aid. Gain insights into regulatory requirements, ISO standards, and the integration of deep learning in medical imaging. Discover the potential of QML in healthcare, particularly in neuroimaging for Alzheimer's disease. Access additional resources on FDA regulations, quantum technologies in healthcare, and the future of QML neuroimaging.

This Week: “FDA 510k/De Novo & QML Neuroimaging for Alzheimer’s” am PST Thursday 11/17 Discussion 57.